title: Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin.
abstract: OBJECTIVE
  To record the efficacy and toxicity of combining bevacizumab with cisplatin in treating malignant pleural effusion and ascites through intrapleural and intraperitoneal infusion.
  
  
  METHODS
  Forty-three patients were admitted to the Oncology Department of Yantai Yuhuangding Hospital with confirmed malignant effusion since January, 2011. Twenty of them received intrapleural and intraperitoneal perfusion of 200 mg bevacizumab plus 60 mg cisplatin every three weeks, and 23 patients received 60 mg cisplatin alone after draining effusion as much as possible. Reduction of effusion was determined by type-B ultrasonography.
  
  
  RESULTS
  The complete remission rate and effective rate of bevacizumab group was superior to that of the cisplatin group. The quality of life recovery rate of bevacizumab group was superior to that of the cisplatin group. The anhelation and abdominal distention of bevacizumab group was significantly improved. There was no significant difference in level III/IV toxicities and adverse effects between two groups.
  
  
  CONCLUSIONS
  Bevacizumab significantly improved the objective response rate and quality of life of patients with malignant pleural effusion and ascites, while not causing notable adverse events.
authors.affiliation: Departments of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Lixin
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Zhaohua
authors.initials: Z
authors.lastname: Gong
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Baohong
authors.initials: B
authors.lastname: Hu
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Ma
authors.affiliation: Central Laboratory, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Jiahui
authors.initials: J
authors.lastname: Wang
authors.affiliation: Central Laboratory, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Hongjin
authors.initials: H
authors.lastname: Chu
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China.
authors.forename: Liangming
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China sunping20039@hotmail.com chenjianyt@163.com.
authors.forename: Ping
authors.initials: P
authors.lastname: Sun
authors.affiliation: Departments of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China Central Laboratory, Yantai Yuhuangding Hospital, Affiliated Hospital of Medical College Qingdao University, Yantai, Shandong, P.R. China sunping20039@hotmail.com chenjianyt@163.com.
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy*; D000068258:Bevacizumab / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy*; D011788:Quality of Life; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000068258:Bevacizumab; D002945:Cisplatin
keywords: Bevacizumab; ascites; cisplatin; intrapleural and intraperitoneal chemotherapy; malignant pleural effusion